Breaking News, Collaborations & Alliances

CureVac and Wacker Sign Contract for Manufacturing of Covid-19 Vaccine Candidate

Manufacturing at Wacker’s biotech site in Amsterdam is scheduled to start in the first half of 2021.

By: Contract Pharma

Contract Pharma Staff

CureVac N.V., a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), and Wacker Chemie AG have signed a contract for the manufacturing of CureVac’s COVID-19 vaccine candidate CVnCoV.   Under the terms of the initial agreement, Wacker will ramp up GMP (Good Manufacturing Practice) production of the mRNA drug substance for CVnCoV at its biotech site in Amsterdam in the first half of 2021. Preparations for the start of production, ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters